BOSTON, June 26, 2024 (GLOBE NEWSWIRE) -- Novotech (https://bit.ly/4bpzXtM), an
internationally renowned full-service clinical Contract Research Organization
(CRO) known for its collaboration with biotech firms to accelerate the
development of innovative therapeutics across all phases, has today published a
leading industry report, Radiopharmaceuticals - Global Clinical Trial Landscape
(https://bit.ly/3VHEVMv).
Over the past 25 years cancer treatment has evolved significantly, incorporating
advanced therapies such as target treatments and immunotherapies alongside
traditional methods like surgery and chemotherapy. Recently, the development of
radiopharmaceuticals - targeted radiation therapy - has marked a significant
innovation in treatment, delivering radiation directly to cancer cells, and
minimizing damage to healthy tissue.
This expert report, provided by the Novotech research analyst team free of
charge, highlights a promising new direction in oncology care. The report delves
into the evolving landscape of radiopharmaceuticals including innovations,
approval processes, the funding landscape and opportunities and considerations
for this treatment in future.
The report shows the global clinical trial landscape for radiopharmaceuticals
has seen substantial growth (https://bit.ly/3VHEVMv). Between 2019 and 2024, the
sector experienced a 24.57% annual growth rate in unique trials, with 150
ongoing industry-initiated trials. North America leads this effort, contributing
42% of the global trials, followed by the Asia-Pacific region (28%) and Europe
(26%). The United States is the foremost contributor, accounting for 79% of
North America's trials. Significant activity is also seen in other regions
including Australia, China, and France.
Radiopharmaceutical trials have predominantly focused on oncology with the top
indications being prostate, neuroendocrine, central nervous system (CNS),
gastrointestinal tract, and lung cancers. The regional distribution of trials by
phase showed North America leading in single-country Phase I and II trials,
while Europe exceeded Asia-Pacific in multinational trials across all phases.
In terms of patient recruitment, the landscape reflected similar enrollment
periods across regions, however, the United States led in recruitment efficiency
with 0.34 subjects per site per month, likely due to its advanced infrastructure
and streamlined regulatory processes.
Key takeaways from the report:

  * The radiopharmaceuticals market is expected to grow significantly, with a
    projected compound annual growth rate (CAGR) of 8.4% from 2021 to 2028. The

global radiopharmaceuticals market was valued at $4.8 billion in 2020 and is

    anticipated to reach $9.6 billion by 2028.
  * Oncology remains the dominant therapeutic area, representing approximately
    60% of all radiopharmaceutical clinical trials, followed by cardiology and
    neurology.
  * Recent years have seen an increase in radiopharmaceuticals receiving
    regulatory approval, indicating a positive trend in the development
    pipeline.
  * Major players in the radiopharmaceuticals sector include Novartis, GE
    Healthcare, and Cardinal Health, who lead the way in both market share and
    innovation.
  * Asia-Pacific is emerging as a significant region for radiopharmaceutical
    clinical trials, with countries like China and India showing increased
    activity and investment.
  * Advances in imaging technologies, such as PET and SPECT, are driving the
    development and application of new radiopharmaceuticals, enhancing
    diagnostic accuracy and treatment efficacy.
  * Venture capital and private equity investment in radiopharmaceutical
    companies have surged, with over US$1 billion invested in the last year
    alone, reflecting growing confidence in this sector's potential.

This comprehensive radiopharmaceuticals report is a resource to guide healthcare
professionals, researchers, and organisations in navigating the global trial
landscape.
Download the report here (https://bit.ly/3VHEVMv)
About Novotech Novotech-CRO.com (https://bit.ly/4bpzXtM)
Founded in 1997, Novotech is a global full-service clinical Contract Research
Organization (CRO) focused on partnering with biotech companies to accelerate
the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received
numerous prestigious awards, including the CRO Leadership Award 2023, the Asia
Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific
Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories,
Phase I facilities, drug development consulting, regulatory expertise, and has
experience with over 5,000 clinical projects, including Phase I to Phase IV
clinical trials and bioequivalence studies. With a presence in 34 office
locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a
trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member
visit https://bit.ly/4bpzXtM
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/cdb1a440-14ce-4ab8-a3b0-
8452493d522f
Â